KR101775961B1 - The composition for preventing or treating rheumatoid arthritis comprising a combination extract containing Yamabushitake mushrooms - Google Patents

The composition for preventing or treating rheumatoid arthritis comprising a combination extract containing Yamabushitake mushrooms Download PDF

Info

Publication number
KR101775961B1
KR101775961B1 KR1020150162060A KR20150162060A KR101775961B1 KR 101775961 B1 KR101775961 B1 KR 101775961B1 KR 1020150162060 A KR1020150162060 A KR 1020150162060A KR 20150162060 A KR20150162060 A KR 20150162060A KR 101775961 B1 KR101775961 B1 KR 101775961B1
Authority
KR
South Korea
Prior art keywords
rheumatoid arthritis
weight
mushroom
composition
present
Prior art date
Application number
KR1020150162060A
Other languages
Korean (ko)
Other versions
KR20170058178A (en
Inventor
서문지훈
홍수영
김현규
권오경
Original Assignee
콜마비앤에이치 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 콜마비앤에이치 주식회사 filed Critical 콜마비앤에이치 주식회사
Priority to KR1020150162060A priority Critical patent/KR101775961B1/en
Publication of KR20170058178A publication Critical patent/KR20170058178A/en
Application granted granted Critical
Publication of KR101775961B1 publication Critical patent/KR101775961B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising a complex extract comprising a spore mushroom, a yellow moth, and a sea tangle, and a health functional food composition, wherein the composition has an effect of preventing, treating or improving rheumatoid arthritis.

Description

TECHNICAL FIELD The present invention relates to a composition for prevention or treatment of rheumatoid arthritis,

The present invention relates to a pharmaceutical composition for the prophylaxis or treatment of rheumatoid arthritis, comprising a complex extract comprising 10 to 20% by weight of corn borer, 10 to 20% by weight of sulfur, and 60 to 80% by weight of an aqueous solution.

The present invention also relates to a health functional food composition for preventing or ameliorating rheumatoid arthritis, which comprises a complex extract comprising 10 to 20% by weight of corn borer, 10 to 20% by weight of sulfur, and 60 to 80% by weight of a sea tangle .

Further, the present invention relates to a method for preparing a composition for preventing or treating rheumatoid arthritis, which comprises mixing 10 to 20% by weight of corn borer, 10 to 20% by weight of sulfur, and 60 to 80% will be.

Rheumatoid arthritis is a chronic inflammatory disease that causes synovial hyperplasia and bone or cartilage destruction of the joints. Initially, inflammation occurs in the soft synovial, which mainly surrounds the flexible joint, but gradually spreads to surrounding cartilage and bone, It is a disease that may cause extrapyramidal symptoms such as anemia, dry syndrome, subcutaneous nodule, pulmonary fibrosis, vasculitis, skin ulcer. According to the results of the third National Health and Nutrition Examination Survey conducted in 2005, 2.1% of the adult population aged 19 years or older in Korea had rheumatoid arthritis, which was the fourth highest incidence of musculoskeletal diseases (Hern Namuk et al., 2008).

Cox-2 inhibitors are commonly used for the treatment of rheumatoid arthritis, as in osteoarthritis, and are used for the reduction of acute pain through reduction of inflammation and improvement of joint function. However, for the treatment of rheumatoid arthritis, The effect is difficult to expect (Lee, EE, 2015)

In addition, the use of non-steroidal anti-inflammatory drugs (NSAIDs) to treat rheumatoid arthritis has been shown to improve joint pain and improve symptoms, And gastrointestinal side effects such as gastric duodenal ulcer may become a problem during long-term use. Steroid Hormone System The medication that controls the inflammation, the face should be rounded, the weight gain, diabetes, hypertension, etc.

The development of an effective and safe arthritis treatment with the side effects and defects is continuing, and it is very important to develop a medicament having a low side effect because it is necessary to take the medicine for a long time to treat rheumatoid arthritis It is an urgent matter.

Accordingly, the present inventors have made intensive efforts to develop a prophylactic or therapeutic agent for rheumatoid arthritis, which is harmless to human body. As a result, it has been found that the extract containing Rootstock mushroom, And thus the present invention has been completed.

The main object of the present invention is to provide a pharmaceutical composition for the prophylaxis or treatment of rheumatoid arthritis, which comprises a combined extract comprising 10 to 20% by weight of corn borer, 10 to 20% by weight of sulfur, and 60 to 80% will be.

Another object of the present invention is to provide a health functional food composition for preventing or ameliorating rheumatoid arthritis, which comprises a complex extract comprising 10 to 20% by weight of corn borer, 10 to 20% by weight of sulfur, and 60 to 80% by weight of a sea tangle .

Another object of the present invention is to provide a method for producing a composition for preventing or treating rheumatoid arthritis, which comprises mixing and extracting 10 to 20% by weight of Herring mushroom, 10 to 20% by weight of sulfur, and 60 to 80% .

In one aspect of the present invention, there is provided a method of preventing rheumatoid arthritis comprising a complex extract comprising 10 to 20% by weight of corn borer, 10 to 20% by weight of sulfur, and 60 to 80% Or a pharmaceutical composition for therapeutic use.

In the present invention, the term " Hericium erinaceum "is a type of edible mushroom belonging to the coral spider mushroom and cormorant. It grows on the stem of broad-leaved trees such as oak, oak, and so on from summer to fall. The mushroom god is about 5 to 20 cm in diameter, It is shaped like a ball, and features a number of needles hanging on the side and bottom.

The term "haedongpi" in the present invention senticosus Araliaceae plant in eomnamu (Kalopanax pictum Nakai) is dried. The pharmacological effects of sea tangle have been found to be gastric secretion, gangrene, anti-inflammatory, and antibacterial effects. If you use it as an external medicine, wash it with water or sprinkle it with powder, and use it as a skin disease, ulcer, and wound.

The term "Hwanggi" in the present invention means a perennial herbaceous plant belonging to the soybean family. The root of Hwanggi is used as a medicinal material. In animal experiments, when a large amount of Hwanggi powder was administered to rats, it suppressed the incidence of nephritis, delayed the onset of proteinuria and cholesterol, .

The term "rheumatoid arthritis" in the present invention refers to an inflammatory autoimmune disease that simultaneously affects a plurality of joints, which may result in joint damage due to chronic arthritis or involvement in other organs other than the joint, ≪ / RTI >

The term " autoimmune disease " means a disease in which an immune function abnormality occurs and immune cells responsible for the immune function attack the organs or tissues of the body.

In one embodiment of the present invention, as shown in Table 1, the compound extract prepared by varying the mixing ratio of the mushroom, horsetail, and sea tangle was administered to rats induced by rheumatoid arthritis by zymosan, It was confirmed that all the administration groups were free of biotoxicity (Fig. 2a). Further, in the group administered with the combined extract of 70% by weight of sea tangle, 15% by weight of pine needle mushroom and 15% by weight of erythrocyte compared with the other groups, the inflammation-induced right parenchyma lymph node and the left parenchyma lymph node And the weight difference was small. Thus, it was confirmed that the combined extract prepared according to the mixing ratio had the best anti-inflammatory activity (FIGS. 2A to 2D).

As used herein, the term "prophylactic " may refer to any action that inhibits or delays the onset of rheumatoid arthritis by administering a composition according to the present invention to an individual.

The term "treatment" of the present invention may mean all the actions of improving the symptoms of the disease by administering the composition according to the present invention to a subject suspected of having rheumatoid arthritis.

The above administration means introducing the pharmaceutical composition of the present invention to a patient by any appropriate method. In one embodiment of the present invention, subcutaneous administration is performed, but the administration route of the composition of the present invention is not limited to the target tissue Or < RTI ID = 0.0 > parenteral < / RTI > The frequency of administration of the composition of the present invention is not particularly limited, but it may be administered once a day or divided into several doses.

Such an individual may refer to any animal, including a human, who has or may have developed rheumatoid arthritis. The animal may be, but is not limited to, a mammal such as a cow, a horse, a sheep, a pig, a goat, a camel, a nutrient, a dog, a cat,

In the present invention, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.

As used herein, the term "pharmaceutically acceptable carrier" may refer to a carrier or diluent that does not disturb the biological activity and properties of the compound being injected, without stimulating the organism. The type of the carrier that can be used in the present invention is not particularly limited, and any carrier conventionally used in the art and pharmaceutically acceptable may be used. Non-limiting examples of the carrier include saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more. The carrier may comprise a non-naturally occuring carrier.

In addition, if necessary, other conventional additives such as an antioxidant, a buffer and / or a bacteriostatic agent can be added and used. A diluent, a dispersant, a surfactant, a binder, a lubricant, Pills, capsules, granules or tablets, and the like.

In addition, the pharmaceutical composition of the present invention may contain a pharmaceutically effective amount of a complex extract of Myrrh, Myrtaceae, and Haemodystrophies. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and is generally in the range of 0.001 to 1000 mg / kg, preferably 0.05 To 200 mg / kg, more preferably 0.1 to 100 mg / kg, may be administered once a day to several times per day. For purposes of the present invention, however, the specific therapeutically effective amount for a particular patient will depend upon the nature and extent of the reaction to be achieved, the particular composition, including whether or not other agents are used, the age, weight, Sex and diet of the patient, the time of administration, the route of administration and the rate of administration of the composition, the duration of the treatment, the drugs used or concurrently used with the specific composition, and similar factors well known in the medical arts.

The pharmaceutical composition of the present invention may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer an amount that can achieve the maximum effect in a minimal amount without causing side effects, and can be readily determined by those skilled in the art.

In the present invention, the combined extracts comprising the mushroom, horsetail, and sea tangle may be hot water extracts, but the present invention is not limited thereto.

In the present invention, the hot-water extraction of the hot-water extract may be performed at 80 to 100 ° C for 5 to 7 hours, but is not limited thereto. Specifically, in one embodiment of the present invention, purified water was used as an extracting solvent of Mulberry Mushroom, Hwanggi, and Haengdongpi, and the solvent drainage was conducted at the first order 20 times and the second order 10 times, and the extraction temperature was 95 ° C The extraction was carried out for 4 hours for the first extraction and 2 hours for the second extraction for a total of 6 hours to prepare a hot water extract.

In another aspect, the present invention provides a health functional food composition for preventing or ameliorating rheumatoid arthritis, which comprises a complex extract comprising 10 to 20 wt% of corn borer, 10 to 20 wt% of sulfur, and 60 to 80 wt% of a sea tangle.

In the present invention, the term "health functional food" means the same food as the food for special health use (FoSHU) The food may be prepared in various forms such as tablets, capsules, powders, granules, liquids, and rings to obtain a useful effect for preventing or improving an inflammatory disease.

The health functional food composition of the present invention may further comprise a pharmaceutically acceptable carrier.

There is no particular limitation on the type of food to which the composition containing the complex extract of the present invention can be added, and examples thereof include various drinks, gums, tea, vitamin complex, and health supplement foods. The food composition may be supplemented with other ingredients that do not interfere with the prevention or amelioration of rheumatoid arthritis, and the kind thereof is not particularly limited. For example, various herbal medicine extracts, food-acceptable food-aid additives or natural carbohydrates, such as ordinary foods, may be added as an additional ingredient.

The food-aid additive (excipient) is added to produce a health functional food of each formulation, and a person skilled in the art can appropriately select and use it. For example, various kinds of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, , A stabilizer, a preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated drink, and the like, but the kind is not limited by the above examples.

At this time, the content of the extract contained in the food is not particularly limited, but may be 0.01 to 99% by weight, more preferably 1 to 80% by weight based on the total weight of the food composition.

When the food is a beverage, it may be contained in a proportion of 1 to 30 g, preferably 3 to 20 g based on 100 ml. In addition, the composition may contain additional ingredients which are commonly used in food compositions and which can improve odor, taste, vision and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. In addition, it may include minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn) and copper (Cu) It may also include amino acids such as lysine, tryptophan, cysteine, valine, and the like. In addition, it is also possible to use antiseptics (such as potassium sorbate, sodium benzoate, salicylic acid, and sodium dehydroacetate), disinfectants (such as bleaching powder and highly bleached white powder, sodium hypochlorite), antioxidants (butylhydroxyanilide (BHA), butylhydroxytoluene BHT), etc.), coloring agents (such as tar pigments), coloring agents (such as sodium nitrite and sodium acetic acid), bleaching agents (sodium sulfite), seasoning (such as MSG sodium glutamate), sweeteners (such as hypoglycemia, , Food additives such as flavorings (vanillin, lactones, etc.), swelling agents (alum, potassium hydrogen D-tartrate), emulsifiers, emulsifiers, thickeners, encapsulating agents, gum bases, foam inhibitors, ) Can be added. The additives are selected according to the type of food and used in an appropriate amount.

The health functional food of the present invention can be manufactured by a method commonly used in the art and can be prepared by adding raw materials and ingredients which are conventionally added in the art. Also, unlike general medicine, there is an advantage that there is no side effect that can occur when a medicine is used for a long time by using food as a raw material, and it is excellent in portability.

In the present invention, the term " prevention "is the same as described above, and" improvement "may mean any action that at least reduces the degree of symptom associated with the condition being treated.

In another aspect, the present invention provides a method for preparing a composition for preventing or treating rheumatoid arthritis, which comprises mixing 10 to 20% by weight of cormorillina, 10 to 20% by weight of sulfur, and 60 to 80% .

In the present invention, the extraction may be hot water extraction, and the hot water extraction may be performed at 80 to 100 ° C for 5 to 7 hours, but is not limited thereto.

The complex extract of the present invention, which is prepared by mixing a specific amount of a mushroom, a mushroom, and a sea tiger mushroom of the present invention, has excellent anti-inflammatory effect against a rat model of rheumatoid arthritis induced by zymosan, and thus effectively prevents or cures rheumatoid arthritis .

FIG. 1A is a graph showing the weight change of rats after administration of rheumatoid mushroom, hwanggi (sample 2), and sea tangle (sample 3) when administered to rats in which rheumatoid arthritis was induced.
FIG. 1B is a graph showing changes in the body weight of rats after administration according to the administration of a compound extract having different mixing ratios of Herring mushroom, Hwanggi, and sea tangle to a rheumatoid arthritis-induced rats.
Sample 1: Composite hot-water extract comprising 70% by weight of corn borer, 15% by weight of sulfur, and 15% by weight of a sea tangle;
Sample 2: a composite hydrothermal extract containing 15% by weight of corn borer, 70% by weight of sulfur, and 15% by weight of a sea tangle;
Sample 3: a composite hydrothermal extract containing 15% by weight of corn borer, 15% by weight of sulfur, and 70% by weight of a sea tangle;
Sample 4: Compound ethanol (70%) extract containing 70% by weight of corn borer, 15% by weight of sulfur, and 15% by weight of a vegetable oil;
Sample 5: a composite ethanol (70%) extract containing 15% by weight of corn borer, 70% by weight of sulfur, and 15% by weight of a sea tangle;
Sample 6: a mixed ethanol (70%) extract containing 15% by weight of Pseudomonas aeruginosa, 15% by weight of sulfur and 70% by weight of a sea tangle;
Sample 7: a mixed ethanol (25%) extract containing 70% by weight of Pseudomonas aeruginosa, 15% by weight of sulfur and 15% by weight of a sea tangle;
Sample 8: Compound ethanol (25%) extract containing 15% by weight of corn borer, 70% by weight of sulfur, and 15% by weight of sea tangle;
Sample 9: Compound ethanol (25%) extract (the same as FIG. 2B to FIG. 2D) containing 15% by weight of corn borer, 15% by weight of sulfur, and 70%
FIG. 2A shows the results of the administration of the extracts of rosemary mushroom, hwanggi (sample 2), and sea tangle (sample 3) alone to rats induced by rheumatoid arthritis. Fig. 2 is a graph showing the difference in the weight of the hypopharyngeal lymph nodes.
FIG. 2B is a graph showing the results obtained when the compound extracts having different mixing ratios of the mushroom, horsetail, and sea tangle were administered to a rheumatoid arthritis-induced rats, the weight of the ovarian lymph nodes at the right- FIG.
FIG. 2c is a photograph showing a comparison of the sizes of isolated glandular lymph nodes in the right inflammation-induced region of rats when a compound extraction of different concentrations of the moxifloxacin, ylang-ylang and sea tangle was administered to a rheumatoid arthritis-induced rats .
FIG. 2 (d) is a photograph showing the degree of inflammation of the pre-autopsied rats when the compound extracts of different concentrations of Pseudomonas aeruginosa, Hwanggi, and Haengdongpi were administered to rats induced by rheumatoid arthritis.

Hereinafter, the constitution and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.

Example 1: Preparation of an extract of Mushroom mushroom

For the evaluation of efficacy against rheumatoid arthritis, single extracts of Myringoptera frugosa, Hwanggi, and Haengdongpi and their combined extracts were prepared.

Specifically, Rootworm mushroom was purchased from a Korean sweet mushroom farming association corporation, and Haeodongpyeo and Hwanggi were purchased as domestic products from Gunsan Daily (Seoul). Then, each sample was mixed at a mixing ratio shown in Table 1, To prepare a complex extract. Distilled water, 70% ethanol, and 25% ethanol were used as the extraction solvent. The solvent was drained at the first 20 times and the second 10 times. The extraction temperature was 70 ℃ (25% ethanol, 70% ethanol) 95 ° C (hot water). (25% ethanol, 70% ethanol) in the same conditions as in the mass production process using a vacuum condenser (Heidolph Laborata 20 control, Germany) after the first extraction for 4 hours and the second extraction for 2 hours ), Or 70 [deg.] C (hot water).

division menstruum Mixing ratio (%) Mushroom mushroom Hwanggi Sea tangle Single 1 Heat number 100 - - Single 2 - 100 - Single 3 - - 100 Compound 1 Heat number 70 15 15 Compound 2 15 70 15 Compound 3 15 15 70 Compound 4 70% ethanol 70 15 15 Compound 5 15 70 15 Compound 6 15 15 70 Compound 7 25% ethanol 70 15 15 Compound 8 15 70 15 Composite 9 15 15 70

Example 2: Anti-rheumatoid arthritis effect test of Comvita extract

Example  2-1; Zimosan ( Zymosan ) Judo Rheumatism  Production of arthritic rats and injection of complex extracts

Zymosan was dissolved at a concentration of 60 mg / ml of saline to prepare a rheumatoid arthritis inducer. On the other hand, the mice to be tested were placed in an anesthesia chamber (Matrix, US / VME-2) and anesthetized with diethyl ether. After the rats were anesthetized, 50 mu l (Zymosan 3 mg / rat) of the prepared rheumatoid arthritis inducer was injected subcutaneously under the right hindpaw of the rats using a 26 gauge Hamilton syringe (model 750; Hamilton Company, Reno, NV) The induced mice were prepared.

The single extract and the combined extract of each of the samples prepared in Example 1 were dissolved in purified water at a concentration of 30 mg / 10 ml for 5 days from the day of administration of zymosan to the rats in which the rheumatoid arthritis was induced, and then 0.2 ml (10 ml / kg) (final concentration: 30 mg / kg).

Example 2-2: Toxicity test by comparison of weight of rats

The mice were weighed every 24 hours (day) in the course of administering the extracts for 5 days according to Example 2-1 above.

As a result, it was confirmed that almost no change was observed in the weight of the mice regardless of the kinds of the extracts (FIGS. 1A and 1B). Through these results, it was confirmed that all of the extracts of Mushroom mushroom extract, Hwanggi extract, Haemongbu extract, and their complex extracts did not show toxicity in vivo.

Example 2-3: Anti-inflammatory effect of single extract and complex extract

On the 6th day of the experiment, autopsy was performed and the right and left popliteal lymph nodes (pLN) were separated and weighed. Thereafter, we compared the difference in pLN between the right inflammatory site and the left control site.

As a result, it was confirmed that the weight difference of pLN was smaller in the hot-water extract of Rooting mushroom than that of the sea tangle and the hot-water extract of Yellow mushroom (Fig. 2a). In addition, it was confirmed that the weight of the pLN was smaller in the combined hot water extracts than in the 70% ethanol and 25% ethanol complex extracts, Showing the same tendency as the degree of swelling due to inflammation (Fig. 2B to Fig. 2D). In the case of single extract, the extracts showed the highest anti - inflammatory effect and showed anti - inflammatory effects in the order of sea tangle and sea tangle. Furthermore, the hot - water extracts showed the best anti - inflammatory effects compared to the ethanol extracts.

On the other hand, the antiinflammatory effects of the combined extracts having different mixing ratios of Herring mushroom, Hwanggi, and Haengdongpi were investigated according to extraction solvents and ratios. As a result, Samples 1 to 3 (hot water extract) and Samples 4 to 6 (70% Extract) showed higher anti-inflammatory activity as the mixing ratio of the sea tangle was higher (FIG. 2B). The results showed that the extracts obtained from the extracts obtained from the extracts of Pseudomonas aeruginosa, Pseudomonas aeruginosa, and Pseudomonas aeruginosa showed higher anti-inflammatory activity as the mixing ratio of sea tangle mushroom was higher .

From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.

Claims (8)

A pharmaceutical composition for the prophylaxis or treatment of rheumatoid arthritis, which comprises a hot-water extract comprising Root-mushroom, Hwanggi, and sea tangle.
The pharmaceutical composition according to claim 1, wherein the hydrothermal extract comprises 10 to 20 wt.% Of corn borer, 10 to 20 wt.% Of sulfur, 60 to 80 wt.
The pharmaceutical composition according to claim 1, wherein the hot water is 80 to 100 캜.
The pharmaceutical composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.
A health functional food composition for the prevention or amelioration of rheumatoid arthritis, comprising a hot-water extract containing a mushroom, a mushroom, and a sea tangle.
A method for the preparation of a composition for preventing or treating rheumatoid arthritis, comprising the step of mixing hot water extracts of mushroom, horsetail, and sea tangle with hot water.
The production method according to claim 6, wherein the mushroom, hull, and sea tangle are mixed at a ratio of 10 to 20 wt%, 10 to 20 wt%, and 60 to 80 wt%, respectively.
7. The process according to claim 6, wherein the hot water extraction is carried out at 80 to 100 DEG C for 5 to 7 hours.
KR1020150162060A 2015-11-18 2015-11-18 The composition for preventing or treating rheumatoid arthritis comprising a combination extract containing Yamabushitake mushrooms KR101775961B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150162060A KR101775961B1 (en) 2015-11-18 2015-11-18 The composition for preventing or treating rheumatoid arthritis comprising a combination extract containing Yamabushitake mushrooms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150162060A KR101775961B1 (en) 2015-11-18 2015-11-18 The composition for preventing or treating rheumatoid arthritis comprising a combination extract containing Yamabushitake mushrooms

Publications (2)

Publication Number Publication Date
KR20170058178A KR20170058178A (en) 2017-05-26
KR101775961B1 true KR101775961B1 (en) 2017-09-19

Family

ID=59051941

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150162060A KR101775961B1 (en) 2015-11-18 2015-11-18 The composition for preventing or treating rheumatoid arthritis comprising a combination extract containing Yamabushitake mushrooms

Country Status (1)

Country Link
KR (1) KR101775961B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230057515A (en) 2021-10-21 2023-05-02 주식회사 한미양행 A composition for preventing or treating arthritis comprising a hydrolyzate of Gryllus bimaculatus L. and a complex extract of fermented Acanthopanax sessiliflorus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
phytochemistry, 2015, vol. 115, pp. 231~238(2015.03.18.)*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230057515A (en) 2021-10-21 2023-05-02 주식회사 한미양행 A composition for preventing or treating arthritis comprising a hydrolyzate of Gryllus bimaculatus L. and a complex extract of fermented Acanthopanax sessiliflorus

Also Published As

Publication number Publication date
KR20170058178A (en) 2017-05-26

Similar Documents

Publication Publication Date Title
KR101543775B1 (en) Pharmaceutical composition for preventing or treating thyroid diseases comprising extract from Lonicera caerulea L. car. edulis fruits
KR101579845B1 (en) Composition that comprising fenugreek extract or compound including fenugreek extract for preventing and improving the andropause or male menopause symptom which involves lethargy, hypotrophy, muscle weakness, increasing visceral fat, tiredness and stress, by increasing testosterone level, endurance, muscle mass and decreasing visceral fat and improving blood lipid composition, number of sperm and activation of sperm
KR20150105616A (en) Composition comprising herbal extract for preventing or treating fatty liver disease
KR20140017932A (en) Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange
JP2001342142A (en) Composition for preventing and curing urologic disease
KR101859166B1 (en) A composition for removing hangover comprising an herb extract including ginseng
KR101775961B1 (en) The composition for preventing or treating rheumatoid arthritis comprising a combination extract containing Yamabushitake mushrooms
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
KR101402936B1 (en) Compositon with anti-obesity activity comprising extract of bamboo leaf and scutellaria and use thereof
KR20150137314A (en) Pharmaceutical composition comprising bee venom, melittin or apamin for prevention or treatment of kidney disease
KR101539180B1 (en) Composition comprising flavonoid for preventing or treating lymphedema
KR101910013B1 (en) A composition for improving, preventing and treating of pain comprising herb extract
KR101732483B1 (en) Composition for prevention, improvement or treatment of peripheral neuropathy comprising Forsythiae Fructus extract as effective component
KR101749674B1 (en) Composition comprising Hericium erinaceum extract for prevent, treatment or improvement of inflammatory bone joint diseases
KR100967813B1 (en) A composition comprising the extract of Raphani semen as an active ingredient showing anti-obesity and anti-hyperlipidemia activity
JP2020504144A (en) Composition for preventing or treating gastritis or peptic ulcer
KR101528557B1 (en) A pharmaceutical composition comprising fermented Eastern prickly pear
KR20130129616A (en) Composition comprising aged honey, mulberry and eucommiae cortex for preventing or treatment of arthritis
KR101644755B1 (en) Composition for preventing or treating stroke or degenerative brain disease
KR102160627B1 (en) Pharmaceutical composition for preventing or treating bone disease comprising extracts of branches of Hovenia dulcis Thunb
KR102536959B1 (en) Composition for preventing, improving, or treating cachexia containing extract of Raphani Semen
KR102380248B1 (en) Pharmaceutical composition for the prevention and treatment of benign prostatic hyperplasia, comprising extract of Rosa laevigata Michx. and Cinnamomum cassia (L.) J.Presl
KR101106376B1 (en) A composition comprising the extract of dictyota coriacea treating and preventing neuro-degenerative disease
KR101847479B1 (en) Composition for prevention or treatment of trychophytia comprising Dalbergia odorifera extract
KR101908078B1 (en) Composition for prevention or treatment of trychophytia comprising Alpinia katsumadai Hayata extract

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant